Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers.
Adiponectin, a hormone secreted by adipocytes, has insulin-sensitizing, antidiabetic, antiinflammatory, and antiangiogenic properties. The authors conducted a nested case-control study in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort, a cohort of male Finnish smokers aged 50-69 years at baseline, to test whether prediagnostic adiponectin concentrations are associated with pancreatic cancer. Between January 1985 and October 2004, 311 incident exocrine pancreatic cancer cases were diagnosed among cohort participants with serum samples. Controls (n = 510) were alive and free of cancer at the time the case was diagnosed and were matched to the cases by age and date of blood drawing. The authors used conditional logistic regression adjusted for smoking, blood pressure, and C-peptide level to calculate odds ratios and 95% confidence intervals for pancreatic cancer. Higher adiponectin concentrations were inversely associated with pancreatic cancer (for highest quintile (> 9.8 microg/mL) vs. lowest (< or =4.6 microg/mL), odds ratio = 0.65, 95% confidence interval: 0.39, 1.07; P-trend = 0.04). The inverse association was significant among cases diagnosed 5 or more years after blood collection (n = 238) (for highest quintile vs. lowest, odds ratio = 0.55, 95% confidence interval: 0.31, 0.98; P-trend = 0.03). These results support the hypothesis that higher adiponectin concentrations may be inversely associated with the development of pancreatic cancer.
Stolzenberg-Solomon
Rachael Z
RZ
Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics,National Cancer Institute, 6120 Executive Blvd., Suite 320, Bethesda, MD 20852, USA. rs221z@nih.gov
Weinstein
Stephanie
S
Pollak
Michael
M
Tao
Yuzhen
Y
Taylor
Philip R
PR
Virtamo
Jarmo
J
Albanes
Demetrius
D
D052242:Adiponectin / Q000097:blood*; D000368:Aged; D016022:Case-Control Studies; D004311:Double-Blind Method; D005387:Finland / Q000453:epidemiology; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology; D012042:Registries; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects* / Q000453:epidemiology
D052242:Adiponectin
Am J Epidemiol. 2001 Apr 1;153(7):680-7
11282796
Int J Obes Relat Metab Disord. 2001 Aug;25(8):1225-32
11477508
Diabetes Care. 2007 Mar;30(3):561-7
17327321
Int J Cancer. 2007 May 1;120(9):1993-8
17266034
J Clin Endocrinol Metab. 2007 Apr;92(4):1510-6
17213279
Exp Gerontol. 2007 Jun;42(6):463-71
17507194
Pancreas. 2007 Jul;35(1):16-21
17575540
Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):2101-9
17905943
Am J Clin Nutr. 2007 Sep;86(3):s858-66
18265479
Am J Epidemiol. 2008 Mar 1;167(5):586-97
18270373
Am J Clin Nutr. 2008 Apr;87(4):801-9
18400700
JAMA. 2001 Aug 22-29;286(8):921-9
11509056
Am J Epidemiol. 2002 May 1;155(9):783-92
11978580
Diabetes. 2002 Jun;51(6):1884-8
12031977
Cancer Epidemiol Biomarkers Prev. 2000 Apr;9(4):403-12
10794485
JAMA. 2000 May 17;283(19):2552-8
10815119
Cancer Causes Control. 2000 Dec;11(10):915-23
11142526
Gastroenterology. 2001 Apr;120(5):1263-70
11266389
Cancer Causes Control. 2002 Jun;13(5):417-26
12146846
Acta Oncol. 2002;41(4):381-8
12234031
Lancet. 2003 Jan 18;361(9353):226-8
12547549
Diabetologia. 2003 Apr;46(4):459-69
12687327
Heart. 2003 Jun;89(6):663
12748229
Br J Cancer. 2003 Aug 4;89(3):519-23
12888824
Histol Histopathol. 2004 Jul;19(3):999-1011
15168361
Mol Cancer. 2003 Jan 6;2:4
12556242
Curr Pharm Des. 2004;10(23):2827-37
15379671
Am J Epidemiol. 1986 Jul;124(1):17-27
3521261
Am J Epidemiol. 1988 Sep;128(3):655-66
2458036
Ann Epidemiol. 1994 Jan;4(1):1-10
8205268
Diabete Metab. 1993 Sep-Oct;19(5):458-62
8056126
Circulation. 1963 Jul;28:52-7
14032101
Cancer Causes Control. 2004 Nov;15(9):873-81
15577289
JAMA. 2005 Jan 12;293(2):194-202
15644546
Atherosclerosis. 2005 Apr;179(2):421-2
15777563
Hypertension. 2005 Jun;45(6):1094-100
15897361
Br J Cancer. 2005 Jun 6;92(11):2076-83
15886696
Pancreatology. 2005;5(6):514-29
16110250
J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27
16204691
J Natl Cancer Inst. 2005 Nov 16;97(22):1688-94
16288122
Br J Cancer. 2005 Nov 28;93(11):1310-5
16288300
Lipids Health Dis. 2005;4:27
16262911
JAMA. 2005 Dec 14;294(22):2872-8
16352795
Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):879-85
16702364
Cell Cycle. 2006 Jun;5(11):1160-3
16721061
J Clin Invest. 2006 Jul;116(7):1784-92
16823476
Cancer Epidemiol Biomarkers Prev. 2006 Jul;15(7):1331-5
16835332
Expert Opin Investig Drugs. 2006 Aug;15(8):917-31
16859394
Clin Chim Acta. 2006 Aug;370(1-2):63-71
16530178
Cancer Res. 2006 Oct 15;66(20):10213-9
17047087
J Clin Endocrinol Metab. 2006 Dec;91(12):5002-7
17003098
J Clin Endocrinol Metab. 2007 Jan;92(1):255-63
17062769
Cancer Causes Control. 2007 Mar;18(2):165-75
17219012